Porous scaffold for mesenchymal cell encapsulation and exosome-based therapy of ischemic diseases

Andreas Czosseck, Max M. Chen, Helen Nguyễn, Annette Meeson, Chuan-Chih Hsu, Chien‐Chung Chen, Thomashire A. George, Shu‐Chian Ruan, Yuan‐Yuan Cheng, Po‐Ju Lin,

Journal of Controlled Release · 2022 · 33 citations · 40 references

DOIFull text

Open access

Concepts

Abstract

Ischemic diseases including myocardial infarction (MI) and limb ischemia are some of the greatest causes of morbidity and mortality worldwide. Cell therapy is a potential treatment but is usually limited by poor survival and retention of donor cells injected at the target site. Since much of the therapeutic effects occur via cell-secreted paracrine factors, including extracellular vesicles (EVs), we developed a porous material for cell encapsulation which would improve donor cell retention and survival, while allowing EV secretion. Human donor cardiac mesenchymal cells were used as a model therapeutic cell and the encapsulation system could sustain three-dimensional cell growth and secretion of therapeutic factors. Secretion of EVs and protective growth factors were increased by encapsulation, and secreted EVs had hypoxia-protective, pro-angiogenic activities in in vitro assays. In a mouse model of limb ischemia the implant improved angiogenesis and blood flow, and in an MI model the system preserved ejection fraction %. In both instances, the encapsulation system greatly extended donor cell retention and survival compared to directly injected cells. This system represents a promising therapy for ischemic diseases and could be adapted for treatment of other diseases in the future.

References

40